KR19990014827A - 로피바카인 히드로클로라이드 모노히드레이트의 신규 제조 방법 - Google Patents
로피바카인 히드로클로라이드 모노히드레이트의 신규 제조 방법 Download PDFInfo
- Publication number
- KR19990014827A KR19990014827A KR1019970708171A KR19970708171A KR19990014827A KR 19990014827 A KR19990014827 A KR 19990014827A KR 1019970708171 A KR1019970708171 A KR 1019970708171A KR 19970708171 A KR19970708171 A KR 19970708171A KR 19990014827 A KR19990014827 A KR 19990014827A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- water
- base
- acetone
- catalyst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NDNSIBYYUOEUSV-RSAXXLAASA-N (S)-ropivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C NDNSIBYYUOEUSV-RSAXXLAASA-N 0.000 title claims description 5
- 229960003691 ropivacaine hydrochloride monohydrate Drugs 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title abstract description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000013078 crystal Substances 0.000 claims description 20
- 239000003054 catalyst Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical group [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 6
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 150000002576 ketones Chemical class 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229950000188 halopropane Drugs 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229960001813 ropivacaine hydrochloride Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- DXDIHODZARUBLA-DTPOWOMPSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid;hydrate Chemical compound O.O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 DXDIHODZARUBLA-DTPOWOMPSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
| 이동 (ppm) | 전체 | 다중도 | 지정 |
| 0.96 | 3H | 3중 피크 | 17 |
| 1.69-2.0 | 7H | 다중 피크 | 11a, 12, 13, 16 |
| 2.18 | 6H | 단일 피크 | 7, 8 |
| 2.41-2.45 | 1H | 넓은 2중 피크 | 11e |
| 3.09-3.18 | 3H | 다중 피크 | 15, 14a |
| 3.70-3.74 | 1H | 넓은 2중 피크 | 14e |
| 4.15-4.19 | 1H | 2쌍의 2중 피크 | 10 |
| 4.78 | 3H | 단일 피크 | H2O, N+-H |
| 7.18-7.28 | 3H | 다중 피크 | 3, 4, 5 |
| 탄소 번호 | 이동 |
| 17 | 11.20 |
| 16 | 17.88 |
| 7, 8 | 18.22 |
| 121 | 21.86 |
| 131 | 23.30 |
| 11 | 29.93 |
| 14 | 53.11 |
| 15 | 58.86 |
| 10 | 66.76 |
| 3, 5 | 129.31 |
| 4 | 129.56 |
| 1 | 132.87 |
| 2, 6 | 136.72 |
| 9 | 169.40 |
| 1 : 지정은 상호변환될 수 있다. |
Claims (21)
- 단계 1 (i) 하기 화학식 II의 라세미 출발 물질인 피페콜록실리디드 히드로클로라이드를 희석된 염기를 사용하여 유기 용매로 추출함으로써 그의 HCl 염으로부터 유리시키는 단계;(ii) 피페콜록실리디드를 물과 함께 안정된 결정계를 형성하는 분리제로 결정화하여 분리하고 희석된 염기를 사용하여 최소 약 1 %(w/w)의 물을 용해시키는 유기 용매에서 추출함으로써 결정 생성물을 그의 염으로부터 유리시켜 화학식 III의 화합물 (S)-피페콜록실리디드를 얻는 단계;단계 2) (i) 염기의 존재하에 1-할로프로판을 사용하고 임의로는 촉매의 존재하에 화학식 III의 S-피페콜록실리디드를 알킬화하고, 가열함으로써 반응을 완결시킨 후, 무기 염을 물로 추출하여 제거하는 단계;(ii) 2(i) 단계에서 얻은 용액을 임의로는 희석시키고 생성물을 하기 화학식 IV의 로피바카인 히드로클로라이드로서 침전시킨 후 분리하는 단계;단계 3) 2 (ii) 단계에서 얻은 생성물 IV를 수성 아세톤에 용해시키며, 생성물 (I)을 아세톤을 첨가하여 침전시키고 생성물을 최종적으로 분리하고 건조하는 단계로 이루어진 하기 화학식 I의 화합물의 제조 방법.화학식 I화학식 II화학식 III화학식 IV
- 제1항에 있어서, 1(ii) 단계에서 물과 함께 안정한 결정계를 형성하는 분리제가 케톤인 방법.
- 제2항에 있어서, 케톤이 아세톤 및 에틸 메틸 케톤으로부터 선택된 것인 방법.
- 제3항에 있어서, 케톤이 아세톤인 방법.
- 제1항에 있어서, 결정화 단계 1(ii)에서 사용된 유기 용매의 물 함량이 15 내지 25 %인 방법.
- 제5항에 있어서, 물 함량이 20 %인 방법.
- 제1항에 있어서, 1(i) 단계에서 희석된 염기가 수산화나트륨, 수산화칼륨, 탄산나트륨 또는 탄산칼륨으로부터 선택된 것인 방법.
- 제1항에 있어서, 1(i) 단계에서 분리제가 L-(-)-디벤조일 타르타르산 또는 L-(-)-디톨루오일 타르타르산인 방법.
- 제8항에 있어서, 분리제가 L-(-)-디벤조일 타르타르산인 방법.
- 제1항에 있어서, 1(ii) 단계의 추출에 사용되는 유기 용매가 이소부틸 메틸케톤, 아세토니트릴, 에탄올, 부탄올 또는 톨루엔으로부터 선택된 것인 방법.
- 제10항에 있어서, 추출에 사용되는 유기 용매가 이소부틸 메틸케톤인 방법.
- 제1항에 있어서, 2(i) 단계의 알킬화가 환류 온도에서 촉매의 존재하에 수행되는 방법.
- 제1항에 있어서, 2(i) 단계의 알킬화제가 1-브로모프로판 또는 1-요오도프로판인 방법.
- 제1항에 있어서, 2(i) 단계의 염기가 탄산염 또는 아민인 방법.
- 제14항에 있어서, 2(i) 단계의 염기가 탄산칼륨, 탄산나트륨 및 트리에틸아민으로부터 선택된 것인 방법.
- 제15항에 있어서, 2(i) 단계의 염기가 탄산칼륨인 방법.
- 제1항에 있어서, 2(i) 단계에서 촉매가 요오드화물 촉매인 방법.
- 제17항에 있어서, 촉매가 요오드화나트륨인 방법.
- 제1항에 있어서, 1(ii) 단계의 반응이 2상 계에서 수행되는 방법.
- 제1항에 있어서, 약 5 %의 물의 추가량이 1(ii) 단계의 반응 동안 존재하는 방법.
- 제1항에 따라 제조된 하기 화학식 I의 로피바카인 히드로클로라이드 모노히드레이트.화학식 I
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501808A SE9501808D0 (sv) | 1995-05-16 | 1995-05-16 | New process |
| SE9501808-1 | 1995-05-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR19990014827A true KR19990014827A (ko) | 1999-02-25 |
| KR100425232B1 KR100425232B1 (ko) | 2004-05-20 |
Family
ID=20398325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970708171A Expired - Lifetime KR100425232B1 (ko) | 1995-05-16 | 1996-04-30 | 로피바카인히드로클로라이드모노히드레이트의신규제조방법 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5959112A (ko) |
| EP (1) | EP0828711B1 (ko) |
| JP (1) | JP3079112B2 (ko) |
| KR (1) | KR100425232B1 (ko) |
| CN (1) | CN1121388C (ko) |
| AR (1) | AR002737A1 (ko) |
| AT (1) | ATE207900T1 (ko) |
| AU (1) | AU696875B2 (ko) |
| BR (1) | BR9608820A (ko) |
| CA (1) | CA2219308C (ko) |
| CZ (1) | CZ290576B6 (ko) |
| DE (1) | DE69616543T2 (ko) |
| DK (1) | DK0828711T3 (ko) |
| EE (1) | EE03394B1 (ko) |
| ES (1) | ES2166888T3 (ko) |
| HU (1) | HU221793B1 (ko) |
| IL (1) | IL118178A (ko) |
| IN (1) | IN185146B (ko) |
| IS (1) | IS1832B (ko) |
| MY (1) | MY115018A (ko) |
| NO (1) | NO309035B1 (ko) |
| NZ (1) | NZ308249A (ko) |
| PL (1) | PL184767B1 (ko) |
| PT (1) | PT828711E (ko) |
| RU (1) | RU2167153C2 (ko) |
| SA (1) | SA96160764B1 (ko) |
| SE (1) | SE9501808D0 (ko) |
| SK (1) | SK281812B6 (ko) |
| TR (1) | TR199701362T1 (ko) |
| TW (1) | TW340841B (ko) |
| UA (1) | UA46770C2 (ko) |
| WO (1) | WO1996036606A1 (ko) |
| ZA (1) | ZA963545B (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309350C (en) | 1997-11-12 | 2007-04-03 | Mitsubishi Chemical Corporation | Purine derivatives and medicaments comprising the same as active ingredient |
| JP3956188B2 (ja) | 1999-05-11 | 2007-08-08 | 三菱化学株式会社 | プリン誘導体2水和物、それを有効成分として含む医薬およびその製造中間体 |
| AU1037701A (en) * | 1999-10-20 | 2001-04-30 | Smithkline Beecham Plc | Process for the preparation of 4-(fluorophenyl)piperidine esters |
| BRPI0104491B8 (pt) * | 2001-10-10 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica. |
| US20060270708A1 (en) * | 2005-05-25 | 2006-11-30 | Navinta Llc | Novel process for preparation of isotonic aqueous injection of ropivacaine |
| WO2009044404A1 (en) * | 2007-10-01 | 2009-04-09 | Ramniwas Goel | Process for the preparation of (s)-ropivacaine hydrochloride monohydrate |
| CN102093284B (zh) * | 2010-12-29 | 2013-05-08 | 宜昌人福药业有限责任公司 | 富集哌啶-2-甲酰苯胺类旋光化合物的方法 |
| WO2014009964A1 (en) * | 2012-07-11 | 2014-01-16 | Neon Laboratories Limited | Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide |
| CN103086954A (zh) * | 2013-02-04 | 2013-05-08 | 山东省医药工业研究所 | 一种制备罗哌卡因的方法 |
| CN104003930B (zh) * | 2014-06-13 | 2016-06-08 | 山东金诃药物研究开发有限公司 | 一种盐酸罗哌卡因的制备方法 |
| CN113105386B (zh) * | 2021-04-10 | 2022-11-25 | 河北一品制药股份有限公司 | 一种盐酸罗哌卡因一水合物工业化的制备方法 |
| CN114524763A (zh) * | 2022-03-11 | 2022-05-24 | 山东科源制药股份有限公司 | 一种制备盐酸罗哌卡因杂质(r)-n-(2,6-二甲苯基)哌啶-2-甲酰胺方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE341404B (ko) * | 1967-05-18 | 1971-12-27 | Sterling Drug Inc | |
| EP0151110B1 (en) * | 1983-08-01 | 1989-03-01 | Astra Läkemedel Aktiebolag | L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same |
| SE451840B (sv) * | 1986-01-03 | 1987-11-02 | Astra Laekemedel Ab | Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning |
| SU1579455A3 (ru) * | 1987-07-01 | 1990-07-15 | Астра Лекемедель Актиеболаг (Фирма) | Способ получени оптически чистого моногидрата S-(-)-1-пропил-2 @ ,6 @ -пипеколоксилидид гидрохлорида |
-
1995
- 1995-05-16 SE SE9501808A patent/SE9501808D0/xx unknown
-
1996
- 1996-04-19 IN IN837DE1996 patent/IN185146B/en unknown
- 1996-04-30 SK SK1512-97A patent/SK281812B6/sk not_active IP Right Cessation
- 1996-04-30 PL PL96323461A patent/PL184767B1/pl unknown
- 1996-04-30 NZ NZ308249A patent/NZ308249A/en not_active IP Right Cessation
- 1996-04-30 BR BR9608820A patent/BR9608820A/pt not_active Application Discontinuation
- 1996-04-30 TR TR97/01362T patent/TR199701362T1/xx unknown
- 1996-04-30 ES ES96914488T patent/ES2166888T3/es not_active Expired - Lifetime
- 1996-04-30 AU AU57832/96A patent/AU696875B2/en not_active Expired
- 1996-04-30 US US08/647,994 patent/US5959112A/en not_active Expired - Lifetime
- 1996-04-30 CA CA002219308A patent/CA2219308C/en not_active Expired - Fee Related
- 1996-04-30 KR KR1019970708171A patent/KR100425232B1/ko not_active Expired - Lifetime
- 1996-04-30 CZ CZ19973452A patent/CZ290576B6/cs not_active IP Right Cessation
- 1996-04-30 DK DK96914488T patent/DK0828711T3/da active
- 1996-04-30 EE EE9700301A patent/EE03394B1/xx unknown
- 1996-04-30 HU HU9900327A patent/HU221793B1/hu active IP Right Grant
- 1996-04-30 EP EP96914488A patent/EP0828711B1/en not_active Expired - Lifetime
- 1996-04-30 JP JP08534738A patent/JP3079112B2/ja not_active Expired - Lifetime
- 1996-04-30 AT AT96914488T patent/ATE207900T1/de active
- 1996-04-30 CN CN96195279A patent/CN1121388C/zh not_active Expired - Lifetime
- 1996-04-30 WO PCT/SE1996/000563 patent/WO1996036606A1/en not_active Ceased
- 1996-04-30 DE DE69616543T patent/DE69616543T2/de not_active Expired - Lifetime
- 1996-04-30 UA UA97126021A patent/UA46770C2/uk unknown
- 1996-04-30 PT PT96914488T patent/PT828711E/pt unknown
- 1996-04-30 RU RU97120751/04A patent/RU2167153C2/ru active
- 1996-05-03 ZA ZA963545A patent/ZA963545B/xx unknown
- 1996-05-05 SA SA96160764A patent/SA96160764B1/ar unknown
- 1996-05-06 TW TW085105371A patent/TW340841B/zh not_active IP Right Cessation
- 1996-05-07 AR ARP960102486A patent/AR002737A1/es unknown
- 1996-05-07 IL IL11817896A patent/IL118178A/xx not_active IP Right Cessation
- 1996-05-16 MY MYPI96001857A patent/MY115018A/en unknown
-
1997
- 1997-11-04 IS IS4607A patent/IS1832B/is unknown
- 1997-11-13 NO NO975220A patent/NO309035B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996012700A1 (en) | Process for preparing levobupivacaine and analogues thereof | |
| KR19990014827A (ko) | 로피바카인 히드로클로라이드 모노히드레이트의 신규 제조 방법 | |
| EP0828735A1 (en) | Process for preparing 4-aryl-piperidine derivatives | |
| EP1136470B1 (en) | Process for the preparation of a piperazine derivative | |
| EP1399422A2 (en) | Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl] -1-hydroxybutyl] -a,a-dimethylbenzene acetic acid and its hydrochloride | |
| JPH0521105B2 (ko) | ||
| BRPI0619276A2 (pt) | processo para a preparação de gentisato de (r)- ou (s)-amlodipina opticamente puro | |
| WO2002068391A1 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
| MXPA97008494A (en) | New process for the preparation of clorhidratode ropivacain monohidrat | |
| HK1009805B (en) | New process for the preparation of ropivacaine hydrochloride monohydrate | |
| CZ20023694A3 (cs) | Tosylátové soli 4-(p-fluorfenyl)-piperidin-3-methanolů | |
| KR102779909B1 (ko) | 이소퀴놀린술포닐클로라이드 산부가염 및 그 제조 방법 | |
| US9718777B2 (en) | Process for the preparation of high purity miglustat | |
| US20040039206A1 (en) | Process for resolving racemic mixtures of piperidine derivatives | |
| HRP960445A2 (en) | New process for the preparation of ropivacaine hydrochloride monohydrate | |
| EP1716154A1 (en) | Process for the preparation of olanzapine form 1 useful as antipsychotic drug | |
| JPH08325262A (ja) | (+)−3−フェニル−5−{2−(1−ピロリジニルメチル)ブチリル}イソオキサゾールおよびその塩の製造法 | |
| SI21746A (sl) | Kristalne oblike olanzapina in postopki za njihovo pripravo | |
| KR20030063905A (ko) | 피페리딘 유도체의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19971115 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20010413 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20030430 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20031230 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20040318 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20040319 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20070112 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20080117 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090121 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100122 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110225 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120228 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20130221 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130221 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20140220 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140220 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20150226 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150226 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20160218 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160218 Start annual number: 13 End annual number: 13 |
|
| PC1801 | Expiration of term |